Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy

Trial Profile

Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ANB 020 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AnaptysBio
  • Most Recent Events

    • 07 Nov 2017 According to an AnaptysBio media release, as of October 31, 2017, 75 percent of the study has been enrolled and the top-line data are expected in the first quarter of 2018.
    • 11 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 11 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top